MedTrace Logo

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05008055 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Capivasertib

Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-03
Primary Completion
2023-08-22
Completion
2024-10-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Denmark
  • France
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008055 on ClinicalTrials.gov